PPAR-γin the Cardiovascular System
| Autor: | Michael G. Usher, Richard M. Mortensen, Sheng-Zhong Duan, Christine Y. Ivashchenko |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
education Peroxisome proliferator-activated receptor 030204 cardiovascular system & hematology Biology behavioral disciplines and activities PPAR agonist 03 medical and health sciences 0302 clinical medicine Mediator Internal medicine mental disorders Drug Discovery medicine Glucose homeostasis Pharmacology (medical) lcsh:QH301-705.5 030304 developmental biology chemistry.chemical_classification 0303 health sciences Lipid metabolism medicine.disease Endocrinology lcsh:Biology (General) Nuclear receptor chemistry Adipogenesis Heart failure psychological phenomena and processes |
| Zdroj: | PPAR Research, Vol 2008 (2008) |
| ISSN: | 1687-4765 1687-4757 |
| DOI: | 10.1155/2008/745804 |
| Popis: | Peroxisome proliferator-activated receptor-γ(PPAR-γ), an essential transcriptional mediator of adipogenesis, lipid metabolism, insulin sensitivity, and glucose homeostasis, is increasingly recognized as a key player in inflammatory cells and in cardiovascular diseases (CVD) such as hypertension, cardiac hypertrophy, congestive heart failure, and atherosclerosis. PPAR-γagonists, the thiazolidinediones (TZDs), increase insulin sensitivity, lower blood glucose, decrease circulating free fatty acids and triglycerides, lower blood pressure, reduce inflammatory markers, and reduce atherosclerosis in insulin-resistant patients and animal models. Human genetic studies on PPAR-γhave revealed that functional changes in this nuclear receptor are associated with CVD. Recent controversial clinical studies raise the question of deleterious action of PPAR-γagonists on the cardiovascular system. These complex interactions of metabolic responsive factors and cardiovascular disease promise to be important areas of focus for the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|